Ginkgo Bioworks Narrows Quarterly Loss to $0.640 per Share, Beats Analyst Estimates
Key Facts
Ginkgo Bioworks reported third-quarter results on November 5, 2026, posting a loss of $0.640 per share, below analysts’ expected loss of $1.010 by $0.37 per share. Investing.com reported that the company generated revenue of $28 million during the quarter, versus a consensus estimate of $21.57 million. The comparison between the actual loss and the estimate shows that the earnings-per-share beat came from a narrower loss, not from turning a profit. The figures were part of the company’s third-quarter results, announced on November 5. Revenue also exceeded the consensus estimate for the same period.
Third-quarter revenue was $28 million, down 6% from $29 million in the same period of 2025, according to the results statement accompanying the company’s filing with the U.S. Securities and Exchange Commission. On a quarterly basis, revenue rose from $20 million in the second quarter of 2026. Together, the comparisons put revenue’s trajectory in context: a year-over-year decline alongside an increase from the previous quarter. The results statement, in the information available, did not detail the drivers of this change. Revenue therefore came in above the consensus estimate of $21.57 million, despite remaining below its level in the same period a year earlier.
The GAAP loss from continuing operations narrowed to $41 million in the third quarter of 2026, compared with a loss of $73 million in the third quarter of 2025, according to the company’s statement. This reflects a year-over-year reduction in the loss from ongoing operations. The adjusted EBITDA deficit also improved to $22 million from $53 million in the same period a year earlier. The company cited the comparison in its quarterly results summary. The figures remain losses, despite being lower than last year’s levels.
On liquidity, cash, cash equivalents and marketable securities totaled $285 million as of September 30, 2026, according to the results statement. The company recorded cash burn of $27 million during the third quarter. Ginkgo maintained its forecast for full-year 2026 total cash burn at between $125 million and $150 million. This range sets out the financial guidance the company reaffirmed after reporting results. The liquidity balance and quarterly cash burn also provide financial context alongside the revenue and loss figures.
Chief Executive Jason Kelly said the company announced during the quarter the sale of a self-operating laboratory to pharmaceutical company Novo, along with new government contracts with ARPA-H and the U.S. National Science Foundation. The company said its subcontract under the ARPA-H GIVE program could be worth up to $17.5 million, supporting the manufacture of RNA medicines using its systems. It also reported that 22 customers signed up for its ADME service during the quarter, 20 of them for the first time. These announcements combine a laboratory deal, government contracts and growth in the ADME service’s new customer base. The details appeared in the results statement accompanying the company’s filing.
The company had set its results presentation and Q&A call for November 5 at 4:30 p.m. Eastern time, according to its announcement. The call was scheduled for the same day the company announced its quarterly results, following publication of the news on November 5, 2026. The announcement said the call would be held by video. It was also the company’s announced forum for presenting and discussing the results. In the same statement, Ginkgo reaffirmed its forecast range for total cash burn for the year.